XXXX inhibitors. Current clinical experience.

@entity1 @entity8444 @entity3413 @entity908 @entity9958 @entity1670 @entity5753 @entity177 @entity205 @entity121 @entity8445 @entity165
@entity5753 and @entity3413 are the 2 best-known members of the class of hypolipidaemic agents known as @entity8444 inhibitors. Clinical experience with @entity5753 includes over 5000 @entity1 , 700 of whom have been treated for 2 years or more, and experience with @entity3413 includes over 3500 @entity1 , of whom 350 have been treated for 18 months or more. @entity5753 has been marketed in the United States for over 6 months. Both agents show substantial clinical efficacy, with reductions in total @entity165 of over 30% and in LDL- @entity165 of 40% in clinical studies. Modest increases in HDL- @entity165 levels of about 10% are also reported. Clinical tolerability of both agents has been good, with fewer than 3% of @entity1 withdrawn from treatment because of clinical adverse experiences. Ophthalmological examinations in over 1100 @entity1 treated with one or the other agent have revealed no evidence of significant short term (up to 2 years) cataractogenic potential. One to 2% of @entity1 have elevations of serum transaminases to greater than 3 times the upper limit of normal. These episodes are asymptomatic and reversible when therapy is discontinued. Minor elevations of @entity908 kinase levels are reported in about 5% of @entity1 . @entity121 , associated in some cases with @entity9958 , and in 2 cases with transient @entity177 , has been rarely reported with @entity5753 , especially in @entity1 concomitantly treated with @entity205 , @entity8445 or @entity1670 . @entity5753 and @entity3413 are both effective and well-tolerated agents for lowering elevated levels of serum @entity165 . As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.
